New drug combo shows promise for Tough-to-Treat anal cancer
NCT ID NCT06669572
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, lenvatinib and pembrolizumab, can shrink or control advanced anal or rectal cancer that has spread and stopped responding to standard chemotherapy. About 35 adults with this type of cancer will receive the drug combination. The goal is to see how many patients experience tumor shrinkage or disease stabilization.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple injection treat leg skin cancer?
- Experimental drug aims to supercharge immune system before cancer surgery
- Blood test may predict throat cancer comeback
- Smoking and drinking leave genetic marks in mouth cells that may lead to cancer
- Lung cancer trial matches drugs to genes: a step toward personalized treatment
- New study aims to spare oral cancer patients from unnecessary neck surgery